Help support women on their vaginal atrophy journey
Prescribing and Adverse event reporting information for BlisselⓇ can be found here.
Women may want their healthcare professional to lead conversations about VA, even though understanding the condition is important to them.1
You can help stop the progressive changes due to vaginal atrophy (VA) with earlier diagnosis, and support women’s quality of life.2-4
Please refer to safety information below.
Prescribing and adverse event reporting information can be found at the end of this video.
The diagnosis of vaginal atrophy is not always straightforward
Complicating the diagnosis of vaginal atrophy is the fact that it can present in various ways, including vaginal dryness, dysuria, itching, burning, and pain during sex.5
Women may be reluctant to discuss the symptoms of vaginal atrophy, due to feelings such as discomfort, concern that the topic isn’t appropriate to raise, or the belief that nothing can be done.6
Prescribing and adverse event reporting information can be found at the end of this video.
Prescribing and Adverse event reporting information for BlisselⓇ can be found here.
Women may want their healthcare professional to lead conversations about VA, even though understanding the condition is important to them.1
You can help stop the progressive changes due to vaginal atrophy (VA) with earlier diagnosis, and support women’s quality of life.2-4
Prescribing and adverse event reporting information can be found at the end of this video.
Prescribing and adverse event reporting information can be found at the end of this video.
The diagnosis of vaginal atrophy is not always straightforward
Complicating the diagnosis of vaginal atrophy is the fact that it can present in various ways, including vaginal dryness, dysuria, itching, burning, and pain during sex.5
Women may be reluctant to discuss the symptoms of vaginal atrophy, due to feelings such as discomfort, concern that the topic isn’t appropriate to raise, or the belief that nothing can be done.6
My Blissel® Time to talk
Video Library
A library of discussions led by national experts Dr Anne Connolly, Dr Diana Mansour and Nurse Specialist Consultant Nikki Noble.
The videos cover a range of very useful, relevant and important topics including, the signs and symptoms of VA, how to make the diagnosis and the impact of vaginal atrophy on a patients quality of life.
Prescribe Blissel® by brand for your patients.
Blissel® is the first and only prescribable estriol containing gel for the treatment of vaginal atrophy7,8
Please refer to safety information below.
Please refer to the Summary of Product Characteristics before prescribing.8
Patients have difficulty discussing their condition
For reasons that are understandable, women may hesitate when discussing vaginal symptoms.6
Whilst there can be many motivations, they can commonly include embarrassment, feeling the discussion is inappropriate, or that nothing can be done.6
Blissel®treats the bothersome symptoms of vaginal atrophy
Blissel® is an ultra low dose estriol vaginal gel containing 50 micrograms per dose (1 gram) of estriol, indicated for treating the symptoms of vaginal atrophy due to oestrogen deficiency in postmenopausal women.7,8
Upcoming Webinars 2026
Our next FREE ONLINE Webinar is on 14th April 2026 between 7.30 – 9.30 pm
More information will be available soon.
How BlisselⓇ
Works
Efficacy
Dosing
Ultra low dose estriol vaginal gel7,8
Prescribing and Adverse event reporting information for BlisselⓇ can be found here.
Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Consilient Health (UK) Ltd, No. 1 Church Road, Richmond upon Thames, Surrey TW9 2QE UK or drugsafety@consilienthealth.com
- Krychman M, et al. J Sex Med 2017;14:425-433.
- Moral E, et al. Menopause. 2018;25(12):1418-23.
- Cagnacci A, et al. Climacteric. 2019;22(1):85-89.
- NAMS position statement. Menopause. 2020;27(9):976-92.
- Palma F, et al. Maturitas. 2018;108:18–23.
- Kagan R, et al. Drugs Aging. 2019;36:897–908.
- Cano A, et al. Menopause. 2012;19(10):1130-9.
- Blissel 50 micrograms/g vaginal gel. Summary of product characteristics.
Date of preparation: February 2026 | UK-BLS-615(2)
